COMMUNIQUÉS West-GlobeNewswire

-
CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer
10/09/2025 -
California Schools Get Roadmap to Millions in Mental Health Funding — Anaheim Elementary Unlocks Over $700K Using TadHealth
10/09/2025 -
Beacon Therapeutics to Participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference
10/09/2025 -
Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need
10/09/2025 -
DeepView® System highlighted at the European Burns Association Congress
10/09/2025 -
Catheter Precision Announces Tender Win and First Purchase Order in Croatia
10/09/2025 -
JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation
10/09/2025 -
Picard Announces Appointment of Two New Members to its Board of Directors
10/09/2025 -
Major shareholder announcement
10/09/2025 -
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
10/09/2025 -
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
10/09/2025 -
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
10/09/2025 -
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
10/09/2025 -
Wellcome Leap and Pivotal Commit $100 Million to Women’s Health Research to Deliver Breakthroughs in Years, Not Decades
10/09/2025 -
Eleos Launches Smarter Support for Group Therapy and SUD Care
10/09/2025 -
neurocare group's Apollo TMS Therapy Devices Now Have FDA Clearance to Treat Adolescents Suffering With Major Depression
10/09/2025 -
Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices
10/09/2025 -
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
10/09/2025 -
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program
10/09/2025
Pages